# US 10,307,440 B2 · Use of dextran sulfate > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,307,440 B2 - Document ID: US10307440B2 - Status: Granted - Kind: B2 - Application number: 15/001,380 - Filed: 2016-01-20 - Published: 2016-05-19 - Granted: 2019-06-04 - Earliest claimed: 2002-11-28 - Assignees: Tx Medic AB - Applicants: TX Medic AB - Inventors: Bo Nilsson; Olle Korsgren - Web page: https://patentgrep.com/patent/US10307440B2 ## CPC - A61K 31/737: Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate (A61K31/727 takes precedence) - A61K 31/721: Dextrans - A61K 35/39: Pancreas; Islets of Langerhans (Langerhans cells of epidermis A61K35/36) - A61L 27/3804: {characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells} - A61L 27/3839: {characterised by the site of application in the body (materials for artificial blood vessels A61L27/507; materials for use in artificial skin A61L27/60)} - A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)} - A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] - A61P 37/00: Drugs for immunological or allergic disorders - A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - A61L 2300/232: Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides - A61L 2300/41: Anti-inflammatory agents, e.g. NSAIDs - A61L 2300/45: Mixtures of two or more drugs, e.g. synergistic mixtures - A61L 2300/64: Animal cells - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract A graft composition intended for transplantation into a human patient comprises an injection solution comprising an isolated therapeutic cell transplant, wherein the therapeutic cell transplant is therapeutic to a human patient, and dextran sulfate, or a pharmaceutically acceptable salt thereof, having an average molecular weight of less than 20,000 Da. ## Claims ### Claim 1 A graft composition intended for transplantation into a human patient, comprising an injection solution which is pharmaceutically acceptable for human injection and which comprises an isolated therapeutic cell transplant, wherein the therapeutic cell transplant is therapeutic to a human patient and comprises cells selected from the group consisting of insulin-producing beta-cells and embryonic xenogeneic neural cells, and dextran sulfate, or a pharmaceutically acceptable salt thereof, having an average molecular weight of less than 20,000 Da. ### Claim 2 (depends on 1) The graft composition according to claim 1, wherein said dextran sulfate, or said pharmaceutically acceptable salt thereof, has an average molecular weight of less than 10,000 Da. ### Claim 3 (depends on 2) The graft composition according to claim 2, wherein said dextran sulfate, or said pharmaceutically acceptable salt thereof, has an average sulfur content of 10 to 25%. ### Claim 4 (depends on 3) The graft composition according to claim 3, wherein said dextran sulfate, or said pharmaceutically acceptable salt thereof, has an average sulfur content of 15 to 20%. ### Claim 5 (depends on 1) The graft composition according to claim 1, wherein said dextran sulfate, or said pharmaceutically acceptable salt thereof, has an average molecular weight of about 5,000 Da. ### Claim 6 (depends on 5) The graft composition according to claim 5, wherein said dextran sulfate, or said pharmaceutically acceptable salt thereof, has an average sulfur content of 10 to 25%. ### Claim 7 (depends on 6) The graft composition according to claim 6, wherein said dextran sulfate, or said pharmaceutically acceptable salt thereof, has an average sulfur content of 15 to 20%. ### Claim 8 (depends on 1) The graft composition according to claim 1, wherein said dextran sulfate, or said pharmaceutically acceptable salt thereof, has an average sulfur content of 10 to 25%. ### Claim 9 (depends on 8) The graft composition according to claim 8, wherein said dextran sulfate, or said pharmaceutically acceptable salt thereof, has an average sulfur content of 15 to 20%. ### Claim 10 (depends on 1) The graft composition according to claim 1, wherein said injection solution which is pharmaceutically acceptable for human injection is adapted for injection into the liver via the portal vein of said patient. ### Claim 11 (depends on 1) The graft composition according to claim 1, wherein said injection solution which is pharmaceutically acceptable for human injection comprises saline. ### Claim 12 (depends on 1) The graft composition according to claim 1, wherein a concentration of said dextran sulfate, or said pharmaceutically acceptable salt thereof, in said graft composition is effective to provide a therapeutic concentration of said dextran sulfate, or said pharmaceutically acceptable salt thereof, of less than 5 mg/ml at a transplantation site in said patient. ### Claim 13 (depends on 12) The graft composition according to claim 12, wherein said concentration of said dextran sulfate, or said pharmaceutically acceptable salt thereof, in said graft composition is effective to provide a therapeutic concentration of said dextran sulfate, or said pharmaceutically acceptable salt thereof, of 0.01 to 1.0 mg/ml at a transplantation site in said patient. ### Claim 14 (depends on 13) The graft composition according to claim 13, wherein said concentration of said dextran sulfate, or said pharmaceutically acceptable salt thereof, in said graft composition is effective to provide a therapeutic concentration of said dextran sulfate, or said pharmaceutically acceptable salt thereof, of 0.01 to 0.2 mg/ml at a transplantation site in said patient. ### Claim 15 (depends on 1) The graft composition according to claim 1, wherein the therapeutic cell transplant comprises insulin-producing beta-cells. ### Claim 16 (depends on 15) The graft composition according to claim 15, wherein the insulin-producing beta-cells comprise islets of Langerhans. ### Claim 17 (depends on 1) The graft composition according to claim 1, wherein the therapeutic cell transplant comprises embryonic xenogeneic neural cells.